These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19999898)

  • 1. Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and lipid-lowering therapies among Rhode Islanders with diabetes enrolled in Medicare Part D plans in 2006 and 2007.
    Kogut S; Caffrey A; Pezzullo L
    Med Health R I; 2009 Nov; 92(11):373-6. PubMed ID: 19999898
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    Clin Ther; 2009 Oct; 31(10):2178-88; discussion 2150-1. PubMed ID: 19922889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician-specific variation in medication adherence among diabetes patients.
    Sherman BW; Sekili A; Prakash ST; Rausch CA
    Am J Manag Care; 2011 Nov; 17(11):729-36. PubMed ID: 22084892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
    Gulliford MC; Charlton J; Latinovic R
    J Hum Hypertens; 2005 Feb; 19(2):111-7. PubMed ID: 15361893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
    Vegter S; Nguyen NH; Visser ST; de Jong-van den Berg LT; Postma MJ; Boersma C
    Am J Manag Care; 2011 Sep; 17(9):609-16. PubMed ID: 21902446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
    Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication use and adherence among elderly Medicare beneficiaries with diabetes enrolled in Part D and retiree health plans.
    Stuart B; Simoni-Wastila L; Yin X; Davidoff A; Zuckerman IH; Doshi J
    Med Care; 2011 May; 49(5):511-5. PubMed ID: 21422956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient use of cardiovascular drugs during pregnancy.
    Andrade SE; Raebel MA; Brown J; Lane K; Livingston J; Boudreau D; Rolnick SJ; Roblin D; Smith DH; Dal Pan GJ; Scott PE; Platt R
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):240-7. PubMed ID: 18200619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient.
    Berecek KH; Farag A; Bahtiyar G; Rothman J; McFarlane SI
    Curr Hypertens Rep; 2004 Jun; 6(3):212-4. PubMed ID: 15128474
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products.
    Zhang Y; Lave JR; Donohue JM; Fischer MA; Chernew ME; Newhouse JP
    Med Care; 2010 May; 48(5):409-17. PubMed ID: 20393360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
    Onuigbo MA
    Arch Intern Med; 2009 Oct; 169(19):1810; author reply 1810-1. PubMed ID: 19858442
    [No Abstract]   [Full Text] [Related]  

  • 15. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
    Hudson M; Richard H; Pilote L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 18. Is physician adherence to prescription guidelines a general trait of health care practices or dependent on drug type?--a multilevel logistic regression analysis in South Sweden.
    Ohlsson H; Merlo J
    Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):682-90. PubMed ID: 19437457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
    Moran A; Goldman L
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):606-7. PubMed ID: 18695697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.